Tessa P Sandberg1,2, Iris Sweere3, Gabi W van Pelt4, Hein Putter5, Louis Vermeulen6, Peter J Kuppen4, Rob A E M Tollenaar4, Wilma E Mesker4. 1. Department of Surgery, Leiden University Medical Centrum, Albinusdreef 2, 2333ZA, Leiden, The Netherlands. t.p.sandberg@lumc.nl. 2. Department of Pathology, Leiden University Medical Centrum, Leiden, The Netherlands. t.p.sandberg@lumc.nl. 3. Department of Pathology, Leiden University Medical Centrum, Leiden, The Netherlands. 4. Department of Surgery, Leiden University Medical Centrum, Albinusdreef 2, 2333ZA, Leiden, The Netherlands. 5. Department of Medical Statistics, Leiden University Medical Centrum, Leiden, The Netherlands. 6. Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center & Cancer Center Amsterdam, Amsterdam, The Netherlands.
Abstract
PURPOSE: Lack of expression of the intestinal transcription factor CDX2 in colorectal cancer (CRC) identifies patients with a poor prognosis. This biomarker has previously been suggested to be prognostic in CRCs with a high stromal content based on mRNA expression data. We investigated the prognostic value of CDX2 expression in microsatellite stable CRC stratified by stromal content using microscopy-based techniques. METHODS AND RESULTS: The study included a cohort of 236 patients with stage I-IV CRC. We assessed by microscopy the tumour-stroma ratio (TSR) and the immunohistochemical CDX2 intensity. We found that patients of the stroma-high group had a worse prognosis compared to those of the stroma-low group [disease-free survival in a multivariate analysis (DFSmultivariate) HR 1.52 (95% CI 1.05-2.21)]. In our cohort, low CDX2 expression (14.6%) showed prognostic value for DFSmultivariate [HR 1.93 (95% CI 1.16-3.23)]. Interestingly, when stratifying the cohort by TSR, no prognostic difference was observed related to CDX2 expression in stroma-low tumours. However, CDX2 expression was found to be prognostic within the stroma-high group [DFSmultivariate HR 3.02 (95% CI 1.49-6.13)]. The p value for interaction between TSR and CDX2 status was borderline significant in DFS (p = 0.071). CONCLUSIONS: The present study confirms a poor outcome of patients with stroma-high tumours. Low CDX2 expression in tumours with a high stromal content identified patients with a particularly poor prognosis. The present study did not reveal a clear difference in TSR associated with CDX2 status and survival. This method, solely based on microscopy, identifies patients who have a high risk of relapse and a poor outcome, and who may benefit from targeted therapy.
PURPOSE: Lack of expression of the intestinal transcription factor CDX2 in colorectal cancer (CRC) identifies patients with a poor prognosis. This biomarker has previously been suggested to be prognostic in CRCs with a high stromal content based on mRNA expression data. We investigated the prognostic value of CDX2 expression in microsatellite stable CRC stratified by stromal content using microscopy-based techniques. METHODS AND RESULTS: The study included a cohort of 236 patients with stage I-IV CRC. We assessed by microscopy the tumour-stroma ratio (TSR) and the immunohistochemical CDX2 intensity. We found that patients of the stroma-high group had a worse prognosis compared to those of the stroma-low group [disease-free survival in a multivariate analysis (DFSmultivariate) HR 1.52 (95% CI 1.05-2.21)]. In our cohort, low CDX2 expression (14.6%) showed prognostic value for DFSmultivariate [HR 1.93 (95% CI 1.16-3.23)]. Interestingly, when stratifying the cohort by TSR, no prognostic difference was observed related to CDX2 expression in stroma-low tumours. However, CDX2 expression was found to be prognostic within the stroma-high group [DFSmultivariate HR 3.02 (95% CI 1.49-6.13)]. The p value for interaction between TSR and CDX2 status was borderline significant in DFS (p = 0.071). CONCLUSIONS: The present study confirms a poor outcome of patients with stroma-high tumours. Low CDX2 expression in tumours with a high stromal content identified patients with a particularly poor prognosis. The present study did not reveal a clear difference in TSR associated with CDX2 status and survival. This method, solely based on microscopy, identifies patients who have a high risk of relapse and a poor outcome, and who may benefit from targeted therapy.
Entities:
Keywords:
CDX2 expression; Colorectal cancer; Prognosis; Tumour-stroma ratio
Authors: Esther M de Kruijf; Johanna G H van Nes; Cornelis J H van de Velde; Hein Putter; Vincent T H B M Smit; Gerrit Jan Liefers; Peter J K Kuppen; Rob A E M Tollenaar; Wilma E Mesker Journal: Breast Cancer Res Treat Date: 2010-04-02 Impact factor: 4.872
Authors: Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark Journal: J Natl Cancer Inst Date: 2005-08-17 Impact factor: 13.506
Authors: A Huijbers; R A E M Tollenaar; G W v Pelt; E C M Zeestraten; S Dutton; C C McConkey; E Domingo; V T H B M Smit; R Midgley; B F Warren; E C Johnstone; D J Kerr; W E Mesker Journal: Ann Oncol Date: 2012-08-02 Impact factor: 32.976
Authors: Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Ellen Freed; Natsumi Irahara; Juliet Philips; Jeffrey A Meyerhardt; Jason L Hornick; Ramesh A Shivdasani; Charles S Fuchs; Shuji Ogino Journal: Clin Cancer Res Date: 2009-07-07 Impact factor: 12.531
Authors: I J Goossens-Beumer; E C M Zeestraten; A Benard; T Christen; M S Reimers; R Keijzer; C F M Sier; G J Liefers; H Morreau; H Putter; A L Vahrmeijer; C J H van de Velde; P J K Kuppen Journal: Br J Cancer Date: 2014-05-01 Impact factor: 7.640
Authors: Wilma E Mesker; Gerrit-Jan Liefers; Jan M C Junggeburt; Gabi W van Pelt; Paola Alberici; Peter J K Kuppen; Noel F Miranda; Karin A M van Leeuwen; Hans Morreau; Karoly Szuhai; Rob A E M Tollenaar; Hans J Tanke Journal: Cell Oncol Date: 2009 Impact factor: 6.730
Authors: Wilma E Mesker; Jan M C Junggeburt; Karoly Szuhai; Pieter de Heer; Hans Morreau; Hans J Tanke; Rob A E M Tollenaar Journal: Cell Oncol Date: 2007 Impact factor: 6.730